Reuters logo
BRIEF-Diamyd Medical invests in patent protection for Diamyd
April 5, 2017 / 6:38 AM / 6 months ago

BRIEF-Diamyd Medical invests in patent protection for Diamyd

April 5 (Reuters) - DIAMYD MEDICAL AB

* DIAMYD MEDICAL INVESTS IN BROAD INTERNATIONAL PATENT PROTECTION FOR DIAMYD® AND NEW STUDY DRUG HAS BEEN PRODUCED

* SUCCESSFUL PRODUCTION OF NEW DIAMYD® HAS BEEN CARRIED OUT BY NEW MANUFACTURER AND STUDY DRUGS LASTS UNTIL 2021

* PATENT APPLICATION INVOLVING INTRALYMPHATIC ADMINISTRATION OF ANTIGEN IS IN INTERNATIONAL INVESTIGATION PHASE IN SEVERAL COUNTRIES INCLUDING UNITED STATES, EUROPE, JAPAN AND CHINA

* GRANTED CLAIMS PROVIDE PROTECTION THAT EXTENDS TO 2035

* SUCCESSFUL PRODUCTION OF NEW DIAMYD® HAS BEEN CARRIED OUT BY NEW MANUFACTURER AND STUDY DRUGS LASTS UNTIL 2021 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below